Immunosuppressive agents: generation and consequences of differing dose-response curves.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 1643996)

Published in Proc R Soc Med on March 01, 1972

Authors

M C Berenbaum

Articles by these authors

A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52

Is azathioprine a better immunosuppressive than 6-mercaptopurine? Clin Exp Immunol (1971) 3.47

Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol (1977) 2.89

Postoperative depression of the lymphocyte response to phytohaemagglutinin. Lancet (1967) 2.57

Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49

The expected effect of a combination of agents: the general solution. J Theor Biol (1985) 2.06

In vivo biological activity of the components of haematoporphyrin derivative. Br J Cancer (1982) 1.82

Photodynamic destruction of human bladder carcinoma. Br J Cancer (1975) 1.55

Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. Br J Cancer (1986) 1.53

Time-dependent immunosuppressive effects of anti-thymocyte serum. Nature (1967) 1.48

meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer (1986) 1.47

Dose-response curves for agents that impair cell reproductive integrity. A fundamental difference between dose-response curves of antimetabolites and those for radiation and alkylating agents. Br J Cancer (1969) 1.44

Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer (1991) 1.42

Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res (1974) 1.36

Depression of lymphocyte responses after surgical trauma. Br J Exp Pathol (1973) 1.29

Correlations between methods for measurement of synergy. J Infect Dis (1980) 1.29

The growth of human tumours in immunosuppressed mice and their response to chemotherapy. Br J Cancer (1974) 1.27

In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. Cancer Chemother Rep (1972) 1.26

Cell respiration as a requirement for antibody release in vitro. Nature (1968) 1.21

Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J (1989) 1.19

Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Relation to immunosuppression induced by trauma. Clin Exp Immunol (1976) 1.11

The therapeutic significance of the dose response curve for antilymphocytic serum. Transplantation (1971) 1.02

The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01

Immunosuppression by L-asparaginase. Nature (1970) 0.99

The relation between the physico-chemical properties and immunosuppressive effects of an homologous series of sulphonic acid esters. Immunology (1967) 0.97

Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother (1983) 0.95

The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice. Br J Cancer (1971) 0.95

Effects of L-asparaginase on lymphocyte-target cell reactions in vitro. Nature (1970) 0.95

Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. Br J Cancer (1985) 0.94

Immunosuppressive agents: the design of selective therapeutic schedules. Antibiot Chemother (1969) 0.93

The rabbit VX2 tumour as a model for carcinomas of the tongue and larynx. Acta Otolaryngol (1989) 0.91

Synergy assessment with growth curves. J Infect Dis (1984) 0.90

Radiosensitivity of immunologically activated cells. Nature (1966) 0.89

Minor synergy and antagonism may be clinically important. J Antimicrob Chemother (1987) 0.88

HPD - a study of its components and their properties. Adv Exp Med Biol (1983) 0.87

Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine. Transplantation (1975) 0.87

The localization of haemolytic antibody in sections of lymphoid organs: an improved method. Immunology (1970) 0.84

Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage. J Antimicrob Chemother (1988) 0.84

Role of mitosis and mitotic inhibition in the immunosuppressive action of thioguanine. Nature (1966) 0.83

Consequences of synergy between environmental carcinogens. Environ Res (1985) 0.82

Protective effects of a novel perfluorochemical emulsion in photodynamic therapy. Biomater Artif Cells Immobilization Biotechnol (1992) 0.82

The effect of cysteine on the immunosuppressive activity of busulphan, cyclophosphamide and nitrogen mustard. Br J Cancer (1971) 0.82

Time-dependence and selectivity of immunosuppressive agents. Immunology (1979) 0.82

Re: W. R. Greco et al., Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res., 50: 5318-5327, 1990. Cancer Res (1992) 0.81

Transplantation and immunosuppression. Mod Trends Immunol (1967) 0.81

Effect of cyclophosphamide on the homograft response in the guinea pig. Transplantation (1965) 0.81

Effect of some metabolic inhibitors on plaque formation in Jerne plates. Nature (1967) 0.81

The mode of action of cytotoxic drugs. Proc R Soc Med (1970) 0.80

Differential asparaginase sensitivity of T-cell and B-cell responses. Clin Exp Immunol (1973) 0.80

Porphyrin sensitizers in tumour phototherapy. Novel sensitizers of the chlorin and bacteriochlorin class with amphiphilic properties. J Photochem Photobiol B (1990) 0.79

Letter: Predicting response of human cancer to chemotherapy. Lancet (1974) 0.78

Research ethics and deception. Lancet (1980) 0.78

Immunosuppression by platinum diamines. Br J Cancer (1971) 0.77

Intercellular immunological controls and modulation of cyclic AMP levels. Some doubts. Immunology (1976) 0.77

Neutrophil function during chemotherapy for Hodgkin's disease. Br J Cancer (1981) 0.77

Photodynamic therapy of a mouse glioma: intracranial tumours are resistant while subcutaneous tumours are sensitive. Br J Cancer (1991) 0.77

Autoimmunity and immunosuppression. Proc R Soc Med (1967) 0.75

Concepts for describing the interaction of two agents. Radiat Res (1991) 0.75

Dose-response curves for agents that impair cell reproductive integrity. The relation between dose-response curves and the design of selective regimens in cancer chemotherapy. Br J Cancer (1969) 0.75

Modes of action of immunosuppressive agents. Proc R Soc Med (1967) 0.75

Increased therapeutic efficiency of a lipid-soluble alkylating agent incorporated in liposomes. Br J Cancer (1982) 0.75

Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects. Br J Urol (1979) 0.75

Effect of L-asparaginase on germinal centre haemolysin. Nature (1971) 0.75

Anti-HIV synergy between dextran sulphate and zidovudine. Lancet (1987) 0.75

Growth of human and rat tumours in immunosuppressed mice. J Pathol (1972) 0.75

Antagonism between radiosensitizing agents. Br J Radiol (1988) 0.75

The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil. Chemotherapy (1979) 0.75

The last surviving cancer cell: the chances of killing it. Cancer Chemother Rep (1968) 0.75

Intrathecal interferon, indomethacin, and multiple sclerosis. Lancet (1987) 0.75

Muscle damage and recovery in the rabbit tongue following photodynamic therapy with haematoporphyrin derivative. Acta Otolaryngol (1991) 0.75